DiaMedica Therapeutics Inc. (DMAC)
Largest Insider Buys in Sector
DMAC Stock Price History Chart
DMAC Stock Performance
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Insider Activity of DiaMedica Therapeutics Inc.
Over the last 12 months, insiders at DiaMedica Therapeutics Inc. have bought $6M and sold $0 worth of DiaMedica Therapeutics Inc. stock.
On average, over the past 5 years, insiders at DiaMedica Therapeutics Inc. have bought $3.41M and sold $3.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: STAHLBERG JAN (10 percent owner) — $3M. Von Koch Thomas (10 percent owner) — $3M.
The last purchase of 1,200,000 shares for transaction amount of $3M was made by Von Koch Thomas (10 percent owner) on 2024‑06‑28.
List of Insider Buy and Sell Transactions, DiaMedica Therapeutics Inc.
| 2024-06-28 | 10 percent owner | 1.2M 2.6697% | $2.50 | $3M | 0.00% | |||
| 2024-06-28 | 10 percent owner | 1.2M 2.6697% | $2.50 | $3M | 0.00% | |||
| 2023-11-16 | Chief Business Officer | 20,000 0.0542% | $2.46 | $49,200 | +23.43% | |||
| 2023-06-23 | 10 percent owner | 1.47M 4.4481% | $3.40 | $5M | -33.18% | |||
| 2023-06-23 | Chief Business Officer | 38,364 0.1334% | $3.91 | $150,003 | -33.18% | |||
| 2023-06-23 | director | 65,000 0.2261% | $3.91 | $254,150 | -33.18% | |||
| 2023-06-23 | director | 38,363 0.1334% | $3.91 | $149,999 | -33.18% | |||
| 2023-06-23 | President and CEO | 12,787 0.0445% | $3.91 | $49,997 | -33.18% | |||
| 2023-06-23 | CFO and Secretary | 10,000 0.0348% | $3.91 | $39,100 | -33.18% | |||
| 2023-06-23 | director | 12,787 0.0445% | $3.91 | $49,997 | -33.18% | |||
| 2023-04-10 | Chief Business Officer | 468,750 1.8065% | $1.60 | $750,000 | +79.62% | |||
| 2022-12-09 | director | 37,079 0.1402% | $1.43 | $53,023 | +57.34% | |||
| 2022-12-08 | director | 20,000 0.0735% | $1.40 | $28,000 | +55.90% | |||
| 2022-12-07 | director | 22,574 0.086% | $1.40 | $31,604 | +61.15% | |||
| 2022-12-06 | director | 2,300 0.0083% | $1.35 | $3,105 | +57.39% | |||
| 2022-12-05 | director | 35,000 0.14% | $1.39 | $48,493 | +69.08% | |||
| 2022-12-02 | Sale | director | 2.86M 9.0121% | $1.24 | $3.53M | +47.97% | ||
| 2022-12-02 | director | 2.86M 9.0121% | $1.24 | $3.53M | +47.97% | |||
| 2022-12-01 | director | 46,952 0.1775% | $1.20 | $56,334 | +82.08% | |||
| 2022-11-30 | director | 2,970 0.0112% | $1.19 | $3,534 | +82.77% |
Insider Historical Profitability
| Von Koch Thomas | 10 percent owner | 5526435 12.9241% | $5.46 | 3 | 1 | +7.4% |
| STAHLBERG JAN | 10 percent owner | 5221608 12.2113% | $5.46 | 1 | 0 | |
| TomEnterprise AB | 2855827 6.6786% | $5.46 | 1 | 0 | +16.67% | |
| Wambeke David J. | Chief Business Officer | 527114 1.2327% | $5.46 | 3 | 0 | +23.22% |
| Giuffre Randall Michael | director | 360355 0.8427% | $5.46 | 10 | 0 | +49.77% |
| Pilnik Richard D. | director | 248245 0.5805% | $5.46 | 7 | 0 | +16.67% |
| Pauls Dietrich John | President and CEO | 68591 0.1604% | $5.46 | 5 | 0 | +13.96% |
| Burroughs Amy L. | director | 44950 0.1051% | $5.46 | 1 | 0 | <0.0001% |
| ALCORN HARRY W JR | SVP, Clinical Operations | 43582 0.1019% | $5.46 | 5 | 0 | <0.0001% |
| Kellen Scott | CFO and Secretary | 32290 0.0755% | $5.46 | 6 | 0 | +15.37% |
| Semba Charles Pauling | director | 29943 0.07% | $5.46 | 1 | 0 | <0.0001% |
| Xiao Zhenyu | 7100 0.0166% | $5.46 | 1 | 0 | <0.0001% | |
| Parsons James T. | director | 6100 0.0143% | $5.46 | 1 | 0 | <0.0001% |
| Verdoorn Todd A. | Chief Scientific Officer | 2000 0.0047% | $5.46 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| The Vanguard Group | $2.81M | 2.67 | 1.01M | +26.35% | +$585,442.28 | <0.0001 | |
| Leon G. Cooperman | $2.45M | 2.33 | 883,623 | 0% | +$0 | 0.1 | |
| First Manhattan Co. | $2.35M | 2.24 | 850,038 | +640.81% | +$2.04M | 0.01 | |
| Paragon Associates Paragon Associates Ii Joint Venture | $1.39M | 1.32 | 500,000 | 0% | +$0 | 2.47 | |
| Geode Capital Management | $662,841.00 | 0.63 | 239,235 | +9.35% | +$56,679.58 | <0.0001 | |
| Bleichroeder Lp | $615,818.00 | 0.59 | 222,317 | 0% | +$0 | 0.16 | |
| Susquehanna International Group | $579,850.00 | 0.55 | 209,332 | +657.93% | +$503,345.32 | <0.01 | |
| Northern Trust | $354,059.00 | 0.34 | 127,819 | -4.35% | -$16,104.80 | <0.0001 | |
| Aristides Capital | $294,542.00 | 0.28 | 106,333 | 0% | +$0 | 0.13 | |
| BlackRock | $286,334.00 | 0.27 | 103,370 | -1.3% | -$3,772.73 | <0.0001 | |
| Morgan Stanley | $253,657.00 | 0.24 | 91,573 | -24.32% | -$81,498.87 | <0.0001 | |
| State Street | $184,562.00 | 0.18 | 66,629 | 0% | +$0 | <0.0001 | |
| Catalyst Financial Partners Llc | $94,294.00 | 0.1 | 36,267 | 0% | +$0 | 0.02 | |
| BNY Mellon | $66,479.00 | 0.06 | 24,000 | -29.89% | -$28,344.98 | <0.0001 | |
| Citadel Advisors LLC | $66,535.00 | 0.06 | 24,020 | +5.75% | +$3,614.83 | <0.0001 | |
| Stonebridge Capital Advisors Llc | $55,400.00 | 0.05 | 20,000 | 0% | +$0 | 0.01 | |
| Dimensional Fund Advisors | $46,977.00 | 0.05 | 16,959 | 0% | +$0 | <0.0001 | |
| Jane Street Capital | $42,209.00 | 0.04 | 15,238 | -35.87% | -$23,608.56 | <0.0001 | |
| Charles Schwab | $36,705.00 | 0.04 | 13,251 | 0% | +$0 | <0.0001 | |
| Massmutual Trust Co Fsb Adv | $13,362.00 | 0.01 | 4,824 | 0% | +$0 | <0.0001 | |
| U.S. Bancorp | $12,008.00 | 0.01 | 4,335 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $7,468.00 | 0.01 | 2,696 | -62.88% | -$12,653.50 | <0.0001 | |
| UBS | $5,335.00 | 0.01 | 1,926 | New | +$5,335.00 | <0.0001 | |
| Advisor Group Holdings Inc | $2,770.00 | <0.01 | 1,000 | 0% | +$0 | <0.0001 | |
| Legend Financial Advisors Inc | $2,770.00 | <0.01 | 1,000 | 0% | +$0 | <0.01 | |
| Royal Bank of Canada | $2,000.00 | <0.01 | 845 | -21.9% | -$560.95 | <0.0001 | |
| Toronto-Dominion Bank | $66.00 | <0.01 | 24 | 0% | +$0 | <0.0001 | |
| Wells Fargo | $485.00 | <0.01 | 175 | +1.74% | +$8.31 | <0.0001 |